1. Home
  2. FTI vs UTHR Comparison

FTI vs UTHR Comparison

Compare FTI & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TechnipFMC plc

FTI

TechnipFMC plc

SELL

Current Price

$70.72

Market Cap

27.8B

Sector

Industrials

ML Signal

SELL

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

SELL

Current Price

$543.40

Market Cap

23.1B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
FTI
UTHR
Founded
1884
1996
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.8B
23.1B
IPO Year
2016
1999

Fundamental Metrics

Financial Performance
Metric
FTI
UTHR
Price
$70.72
$543.40
Analyst Decision
Buy
Buy
Analyst Count
22
15
Target Price
$76.59
★ $651.86
AVG Volume (30 Days)
★ 2.5M
695.4K
Earning Date
10-29-2026
10-28-2026
Dividend Yield
★ 0.29%
N/A
EPS Growth
★ 20.42
13.07
EPS
1.53
★ 13.07
Revenue
★ $9,932,600,000.00
$1,483,300,000.00
Revenue This Year
$8.16
N/A
Revenue Next Year
$6.49
$12.09
P/E Ratio
$45.59
★ $42.07
Revenue Growth
★ 9.35
2.38
52 Week Low
$35.29
$409.15
52 Week High
$80.70
$609.35

Technical Indicators

Market Signals
Indicator
FTI
UTHR
Relative Strength Index (RSI) 46.09 60.75
Support Level $70.35 $526.30
Resistance Level $71.97 $576.30
Average True Range (ATR) 1.63 20.15
MACD 0.18 4.50
Stochastic Oscillator 64.08 70.54

Price Performance

Historical Comparison
FTI
UTHR

About FTI TechnipFMC plc

TechnipFMC PLC is the key provider of offshore oilfield services, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea construction services. The company also provides various pieces of surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of Technip and FMC Technologies. Geographically it operates in Latin America generating the maximum revenue, then Europe and Central Asia, Africa, North America, Asia Pacific and Middle East.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: